about
Brivaracetam add-on therapy for epilepsyModifications of antiepileptic drugs for improved tolerability and efficacyProfile of brivaracetam and its potential in the treatment of epilepsyRegulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsyClinical picture of EPM1-Unverricht-Lundborg disease[Brivaracetam for add-on treatment in focal epilepsy].Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.Emerging drugs for epilepsy.Expression of SV2 isoforms during rodent brain development.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Emerging drugs for partial-onset epilepsy: a review of brivaracetamEmerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Brivaracetam for the treatment of epilepsy in adults.Progressive myoclonic epilepsy type 1: Report of an Emirati family and literature review.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Evaluation of brivaracetam: a new drug to treat epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Treatment of Lennox-Gastaut syndrome: overview and recent findings.The photoparoxysmal response: the probable cause of attacks during video games.Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.Synthesis of chiral lactams via asymmetric hydrogenation of α,β-unsaturated nitriles.
P2860
Q24188269-6B1336BD-7347-4E06-BC18-FB6C67623905Q24651951-30492EFC-33C2-40F4-ADBB-DB8C8423746FQ26776317-AC4681BD-3B2C-42D7-87B8-2F2E608E3426Q26859135-3D0509BA-B313-4591-9333-939B6E9A38DBQ28271795-22F011B3-7259-42A9-9D95-BBD891ACEA43Q30390285-7B2F5043-2BCD-44EA-B3AB-A9A32DFCC79CQ34132754-9E1CEEDB-4E6D-43C9-BE49-50B101B114BFQ34688725-164ADCB5-6E1F-46A1-AED4-D8B259CD24CFQ34927836-984163F2-A6AE-4BE3-9735-C85BCBBF77DFQ35761335-6B6E5AF5-9688-419F-88D1-824B5D055307Q36891212-D37AB701-60DE-41C7-98D6-C2AFFEA91BD7Q37754477-F7DD5E27-E7E7-4C7A-8972-79B1691D4BF4Q37831297-30A432F9-CDF7-47EC-AE00-E818CF745B80Q38195636-0162EE07-89CF-4AA6-89B8-FBE44A9858F9Q38350627-04535F76-3AAA-46E2-A559-9FBC35759FA7Q38614499-928D6250-7933-4E47-B653-5461AFB72C0AQ38626838-CC3F3A2A-CDB2-481B-9279-CEB00B60338AQ38652806-AF875607-E5DD-4D74-948B-3E5F5F5201B7Q38739649-C270193A-9D6C-4983-8B96-93ABEBC82100Q38985697-880BC980-49EB-402A-A007-703D50E8C028Q39990727-72ED0DAF-EEE4-46E4-8E59-21534F17BD51Q46719888-8558BB2A-C9CD-410F-8AA7-3E18E4E3FBEFQ48886998-0B542F58-BF89-48E4-B38F-8FAF60F0DC52Q52147702-22482FC9-4442-459E-9579-C296E5ABB83BQ53082614-5902413F-B048-45C2-AFA1-363BCD963078Q53154348-A456C183-BEE2-40E8-AF55-3417DD3CC92C
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Brivaracetam (UCB 34714)
@ast
Brivaracetam (UCB 34714)
@en
Brivaracetam (UCB 34714)
@nl
type
label
Brivaracetam (UCB 34714)
@ast
Brivaracetam (UCB 34714)
@en
Brivaracetam (UCB 34714)
@nl
prefLabel
Brivaracetam (UCB 34714)
@ast
Brivaracetam (UCB 34714)
@en
Brivaracetam (UCB 34714)
@nl
P2860
P3181
P1433
P1476
Brivaracetam (UCB 34714)
@en
P2093
Philipp von Rosenstiel
P2860
P2888
P3181
P356
10.1016/J.NURT.2006.11.004
P407
P577
2007-01-01T00:00:00Z
P5875
P6179
1006350638